Icosavax Past Earnings Performance

Past criteria checks 0/6

Icosavax's earnings have been declining at an average annual rate of -46.5%, while the Biotechs industry saw earnings growing at 16.4% annually. Revenues have been declining at an average rate of 58.9% per year.

Key information

-46.5%

Earnings growth rate

37.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-58.9%
Return on equity-41.6%
Net Marginn/a
Last Earnings Update30 Sep 2023

Recent past performance updates

Recent updates

We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Jul 04
We Think Icosavax (NASDAQ:ICVX) Can Afford To Drive Business Growth

Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Mar 10
Will Icosavax (NASDAQ:ICVX) Spend Its Cash Wisely?

Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Oct 18
Is Icosavax (NASDAQ:ICVX) In A Good Position To Invest In Growth?

Icosavax GAAP EPS of -$0.57

Aug 15

Icosavax to pursue COVID bivalent vaccine in 2023 as biotech highlights near-term milestones

Jul 28

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Jun 22
Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

Mar 24
Here's Why We're Not Too Worried About Icosavax's (NASDAQ:ICVX) Cash Burn Situation

We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Oct 29
We're Hopeful That Icosavax (NASDAQ:ICVX) Will Use Its Cash Wisely

Revenue & Expenses Breakdown

How Icosavax makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ICVX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 230-97360
30 Jun 230-97350
31 Mar 230-93330
31 Dec 221-92300
30 Sep 223-8670
30 Jun 224-99240
31 Mar 226-85190
31 Dec 218-67140
30 Sep 217-53290
30 Jun 216-2550
31 Mar 214-2130
31 Dec 202-1930

Quality Earnings: ICVX is currently unprofitable.

Growing Profit Margin: ICVX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ICVX is unprofitable, and losses have increased over the past 5 years at a rate of 46.5% per year.

Accelerating Growth: Unable to compare ICVX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ICVX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.1%).


Return on Equity

High ROE: ICVX has a negative Return on Equity (-41.62%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies